Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd. It is... It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
- Mechanism
- Curator reviewed · 4 references
The generation of this combo was conceived under the reported activation by the transformation of tegafur to 5-fluorouracil. These findings have convened with results that suggested that the degradation of 5-fluorouracil can be depressed by the addition of uracil. Uracil competitively inhibits the catabolic action of dihydropyrimidine dehydrogenase. This combined activity allows a significant increase in blood and tissue 5-fluorouracil levels by inhibiting its first-pass hepatic metabolism. The active metabolites of tegafur inhibit the enzyme thymidylate synthase (5-fluoro-deoxyuridine-monophosphate) and intercalate into RNA (5-fluorouridine-triphosphate).
- Primary indication
- Tegafur-uracil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinate.Curator reviewed
- Formula / weight
- C12H13FN4O5 · 312.257 g/mol (avg)
- Also known as
- Tegafur/uracil · UFUR
Resolves to
DHMYGZIEILLVNR-UHFFFAOYSA-NSMILESO=C1NC=CC(=O)N1.FC1=CN(C2CCCO2)C(=O)NC1=OWhat you can answer from here — as of April 02, 2025
Which drugs share a target with Tegafur-uracil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account